Do you recommend a trial of biologic therapy in a patient with non-radiographic axSpA on the basis of MRI sacroiliitis and elevated CRP alone, but without any other clinical features of spondyloarthritis?
How do you balance the risk of over-diagnosis with the risk of under-treatment given that the ASAS criteria are not intended to be used for individual diagnosis?